The rise of systems pharmacology in drug discovery and development

Future Medicinal ChemistryVol. 6, No. 16 EditorialThe rise of systems pharmacology in drug discovery and developmentNeil Benson & Piet H van der GraafNeil BensonXenologiq Ltd, Unit 43, Canterbury Innovation Centre, University Road, Canterbury, CT2 7FG, UK & Piet H van der GraafAuthor for correspondence: E-mail Address: p.vandergraaf@lacdr.leidenuniv.nlLeiden Academic Centre for Drug Research, Systems Pharmacology Cluster, 2300 RA Leiden, The NetherlandsPublished Online:19 Nov 2014https://doi.org/10.4155/fmc.14.66AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleReferences1 Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711–715 (2004).Crossref, Medline, CAS, Google Scholar2 Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203–214 (2010).Crossref, Medline, CAS, Google Scholar3 Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32(1), 40–51 (2014).Crossref, Medline, CAS, Google Scholar4 Milligan PA, Brown MJ, Marchant B et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93(6), 502–514 (2013).Crossref, Medline, CAS, Google Scholar5 van der Graaf PH, Gabrielsson J. Pharmacokinetic–pharmacodynamic reasoning in drug discovery and early development. Future Med. Chem. 1(8), 1371–1374 (2009).Link, CAS, Google Scholar6 Gabrielsson J, Green AR, van der Graaf PH. Optimising in vivo pharmacology studies – practical PKPD considerations. J. Pharmacol. Toxicol. Methods 61(2), 146–156 (2010).Crossref, Medline, CAS, Google Scholar7 Gabrielsson J, Fjellstrom O, Ulander J, Rowley M, van der Graaf PH. Pharmacodynamic–pharmacokinetic integration as a guide to medicinal chemistry. Curr. Top. Med. Chem. 11(4), 404–418 (2011).Crossref, Medline, CAS, Google Scholar8 Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic–pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov. Today 12(23–24), 1018–1024 (2007).Crossref, Medline, CAS, Google Scholar9 Danhof M, De Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic–pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29(4), 186–191 (2008).Crossref, Medline, CAS, Google Scholar10 Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol. 49, 291–301 (2009).Crossref, Medline, CAS, Google Scholar11 Langdon G, Davis JD, Mcfadyen LM et al. Translational pharmacokinetic–pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. Br. J. Clin. Pharmacol. 69(4), 336–345 (2010).Crossref, Medline, CAS, Google Scholar12 van der Worp HB, Howells DW, Sena ES et al. Can animal models of disease reliably inform human studies? PLoS Med. 7(3), e1000245 (2010).Crossref, Medline, Google Scholar13 Benson N, Cucurull-Sanchez L, Demin O, Smirnov S, van der Graaf P. Reducing systems biology to practice in pharmaceutical company research; selected case studies. Adv. Exp. Med. Biol. 736, 607–615 (2012).Crossref, Medline, CAS, Google Scholar14 Berg JM, Rogers ME, Lyster PM. Systems biology and pharmacology. Clin. Pharmacol. Ther. 88(1), 17–19 (2010).Crossref, Medline, CAS, Google Scholar15 van der Graaf P. Pharmacometrics and systems pharmacology. CPT Pharmacometrics Syst. Pharmacol. 1, e8 (2012).Google Scholar16 Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic–pharmacodynamic modeling – a new classification of biomarkers. Pharmaceut. Res. 22(9), 1432–1437 (2005).Crossref, Medline, CAS, Google Scholar17 Cucurull-Sanchez L, Spink KG, Moschos SA. Relevance of systems pharmacology in drug discovery. Drug Discov. Today 17(13–14), 665–670 (2012).Crossref, Medline, CAS, Google Scholar18 Ihekwaba AE, Broomhead DS, Grimley RL, Benson N, Kell DB. Sensitivity analysis of parameters controlling oscillatory signalling in the NF-kappaB pathway: the roles of IKK and IkappaBalpha. Systems Biol. 1(1), 93–103 (2004).Crossref, CAS, Google Scholar19 Benson N, Matsuura T, Smirnov S et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3(2), 20120071 (2013).Crossref, Medline, Google Scholar20 Benson N, Metelkin E, Demin O, Li GL, Nichols D, van der Graaf PH. A systems pharmacology perspective on the clinical development of fatty acid amide hydrolase inhibitors for pain. CPT Pharmacometrics Syst. Pharmacol. 3, e91 (2014).Crossref, Medline, CAS, Google Scholar21 Morgan P, van der Graaf PH, Arrowsmith J et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17(9–10), 419–424 (2012).Crossref, Medline, CAS, Google Scholar22 Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153(9), 1837–1846 (2012).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByBiotherapeutics ADME and PK/PD PrinciplesSystems Modeling to Quantify Safety Risks in Early Drug Development: Using Bifurcation Analysis and Agent-Based Modeling as Examples20 May 2021 | The AAPS Journal, Vol. 23, No. 4Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates10 September 2019 | Cancer Medicine, Vol. 8, No. 15Quantitative Systems Pharmacology Model for Alzheimer Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option8 October 2018 | CPT: Pharmacometrics & Systems Pharmacology, Vol. 7, No. 11Impact of a five-dimensional framework on R&D productivity at AstraZeneca19 January 2018 | Nature Reviews Drug Discovery, Vol. 17, No. 3Array of translational systems pharmacodynamic models of anti-cancer drugs22 October 2016 | Journal of Pharmacokinetics and Pharmacodynamics, Vol. 43, No. 6Topics in Mathematical Pharmacology29 July 2015 | Journal of Dynamics and Differential Equations, Vol. 28, No. 3-4Translational pharmacokinetics and pharmacodynamics of monoclonal antibodiesDrug Discovery Today: Technologies, Vol. 21-22Mixture dynamics: Combination therapy in oncologyEuropean Journal of Pharmaceutical Sciences, Vol. 88Systems Pharmacology: An Overview2 December 2016The promises of quantitative systems pharmacology modelling for drug developmentComputational and Structural Biotechnology Journal, Vol. 14Network-based discovery through mechanistic systems biology. Implications for applications – SMEs and drug discovery: where the action isDrug Discovery Today: Technologies, Vol. 15Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps4 May 2015 | Expert Opinion on Drug Metabolism & Toxicology, Vol. 11, No. 5Systems engineering meets quantitative systems pharmacology: from low‐level targets to engaging the host defenses16 March 2015 | WIREs Systems Biology and Medicine, Vol. 7, No. 3 Vol. 6, No. 16 STAY CONNECTED Metrics Downloaded 202 times History Published online 19 November 2014 Published in print October 2014 Information© Future Science LtdFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download